StockData
Q32 Bio Inc. logo

Q32 Bio Inc. (QTTB) shareholders

QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$8.63+0.34 (+4.10%)

Close on Nov 17, 2026Market cap $256.91MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
74.6%
22M of 30M shares
Institutional holders
71
27 new, 8 sold out
Net institutional buying
13M
In Q2 2026
Insider trades, 12 months
4 buys · 11 sales
Net bought $29.50M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vii LLC (11.80%)
4,127,98713.90%13D (active) amendmentJul 16, 2026
Aaron Davis
Joint filing with Boxer Capital Management, LLC (13.30%), Boxer Holdings, LP (13.30%) and 1 more
3,149,31013.30%13G (passive)Jun 30, 2026
ADAR1 Partners, LP
Joint filing with ADAR1 Capital Management, LLC (5.40%), ADAR1 Capital Management GP, LLC (5.40%) and 1 more
3,120,8245.40%13G (passive)Mar 4, 2024
Bvf Partners L P/Il
Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more
2,367,5249.99%13G (passive)May 28, 2026
Boxer Capital Management, LLC
Joint filing with Boxer Holdings, LP (7.90%), Boxer Holdings GP, LLC (7.90%) and 1 more
2,357,9227.90%13G (passive) amendmentSep 30, 2026
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (9.80%), Peter Kolchinsky (9.80%) and 1 more
2,332,4579.80%13G (passive)May 28, 2026
Orbimed Capital Gp Vii LLC
Joint filing with Orbimed Advisors LLC (15.40%)
2,252,98715.40%13D (active) amendmentFeb 18, 2026
Bank Of America Corp /De/2,205,3907.40%13G (passive)Sep 30, 2026
Fhmlsp, L.L.C.
Joint filing with Frazier Life Sciences Public Fund, L.P. (5.90%), Fhmlsp, L.P. (5.90%)
1,755,1165.90%13G (passive)Oct 2, 2026
Point72 Asset Management, L.P.
Joint filing with Point72 Capital Advisors, Inc. (5.70%), Steven A. Cohen (5.70%)
958,7685.70%13G (passive) amendmentMar 31, 2026
Opaleye Management Inc.
Joint filing with Opaleye, L.P. (5.49%), James Silverman (5.49%)
931,0005.49%13G (passive) amendmentJun 30, 2026
Acorn Capital Advisors, GP, LLC
Joint filing with Acorn Bioventures, L.P. (6.70%), Anders Hove (6.70%)
803,4256.70%13D (active)Mar 25, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of QTTBValueChange% of portfolio
Orbimed Advisors LLC4,127,98713.87%$52.59M+1,875,0000.97%
Boxer Capital Management, LLC3,149,31010.58%$40.12MNew3.02%
Atlas Venture Life Science Advisors, LLC2,717,1069.13%$34.62M+625,0003.93%
Bvf Inc/Il2,350,0007.89%$29.94MNew0.77%
Ra Capital Management, L.P.2,332,4577.84%$29.72MNew0.26%
Point72 Asset Management, L.P.1,173,3963.94%$14.95MNew0.02%
Opaleye Management Inc.931,0003.13%$11.86M−325,2281.07%
Logos Global Management LP800,0002.69%$10.19MNew0.44%
SummitTX Capital, L.P.733,7742.46%$9.35MNew0.24%
Vanguard Capital Management LLC518,8031.74%$6.61M+212,4020.00%
Ikarian Capital, LLC430,0001.44%$5.48MNew0.59%
Woodline Partners LP286,2120.96%$3.65MNew0.01%
American Century Companies Inc272,7520.92%$3.47M+253,9820.00%
Sanofi244,0830.82%$3.11M–0.58%
Acadian Asset Management LLC218,2340.73%$2.78M+45,6480.00%
Acorn Capital Advisors, LLC216,1710.73%$2.75M−98,8810.75%
Renaissance Technologies LLC179,6000.60%$2.29M−27,3150.00%
Jane Street Group, LLC162,7470.55%$2.07M+97,1480.00%
Monimus Capital Management, LP132,0360.44%$1.68M−2,2740.39%
Boothbay Fund Management, LLC130,4270.44%$1.66MNew0.02%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267122M74.6%27 / 1813 / 815M2M
Q1 2026539M31.7%11 / 149 / 82M1M
Q4 2025528M27.0%7 / 920 / 80M1M
Q3 2025538M28.3%8 / 1018 / 160M1M
Q2 2025619M30.2%10 / 1219 / 220M1M
Q1 2025739M31.6%8 / 1720 / 260M2M
Q4 20249211M36.9%40 / 2210 / 214M2M
Q3 2024739M30.6%28 / 188 / 82M1M
Q2 2024548M27.1%20 / 166 / 41M0M
Q1 2024387M25.0%38 / 00 / 07M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

24 funds held QTTB in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of QTTBValue% of fundAs of
Vanguard Total Stock Market Index Fund389,1151.31%$4.96M0.00%Jun 30, 2026
Avantis U.S. Small Cap Value ETF128,5100.43%$1.42M0.01%May 31, 2026
Vanguard Extended Market Index Fund119,2690.40%$1.52M0.00%Jun 30, 2026
Ultra-Small Company Fund34,6130.12%$440.97K0.45%Jun 30, 2026
Fidelity Extended Market Index Fund30,0170.10%$331.69K0.00%May 31, 2026
iShares Micro-Cap ETF29,4650.10%$375.38K0.02%Jun 30, 2026
Fidelity Total Market Index Fund16,8010.06%$185.65K0.00%May 31, 2026
Fidelity Series Total Market Index Fund15,3390.05%$169.50K0.00%May 31, 2026
Dimensional U.S. Small Cap ETF14,6520.05%$229.74K0.00%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund8,3250.03%$91.99K0.00%May 31, 2026
Small-Cap Value Portfolio6,2230.02%$79.28K0.02%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund5,9340.02%$75.60K0.00%Jun 30, 2026
U.S. Micro Cap Portfolio4,8900.02%$76.68K0.00%Jul 31, 2026
Vanguard Balanced Index Fund4,4850.02%$57.14K0.00%Jun 30, 2026
Column Small Cap Fund1,9760.01%$21.83K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jodie Pope MorrisonCEO, Director340,0381.14%Oct 14, 2026
Lee KalowskiCFO and President137,1700.46%Oct 14, 2026
Shelia M. VioletteChief Scientific Officer163,1310.55%Oct 14, 2026
Jason CampagnaChief Medical Officer37,5000.13%Feb 26, 2025
Mary ThistleDirector––Jul 21, 2026
David S. GrayzelDirector2,092,1067.03%Jul 21, 2026
Kathleen LaporteDirector5,4310.02%Jul 21, 2026
Diyong XuDirector, 10% owner625,0002.10%Jul 21, 2026
Mark T. IwickiDirector––Jul 21, 2026
Arthur TzianabosDirector7,9830.03%Jul 21, 2026
Sven Ante LundbergDirector1,2000.00%Jul 21, 2026
Isaac MankeDirector53,5210.18%Jul 21, 2026
Genesis GP LLC OrbiMedDirector, 10% owner––Jun 1, 2026
Capital GP VII LLC OrbiMedDirector, 10% owner3,502,98711.77%Jun 1, 2026
Advisors Llc OrbimedDirector, 10% owner2,252,9877.57%Jun 1, 2026
Atlas Venture Associates Opportunity III, L.P.–625,0002.10%Jun 8, 2026
Atlas Venture Opportunity Fund Ill, L.P.–––Jun 8, 2026
Atlas Venture Associates Opportunity III, LLC–––Jun 8, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jodie Pope Morrison
CEO, Director
Oct 6, 2026Sale−3,221$8.32$26.80K340,038
Shelia M. Violette
Chief Scientific Officer
Oct 6, 2026Sale−917$8.32$7.63K126,854
Lee Kalowski
CFO and President
Oct 6, 2026Sale−1,301$8.32$10.82K137,170
Jodie Pope Morrison
CEO, Director
Aug 25, 2026Sale−9,845$16.56$163.03K343,259
Shelia M. Violette
Chief Scientific Officer
Aug 25, 2026Sale−2,798$16.56$46.33K127,771
Lee Kalowski
CFO and President
Aug 25, 2026Sale−3,972$16.56$65.78K138,471
Lee Kalowski
CFO and President
Jul 16, 2026Award+53,250––142,443
Jodie Pope Morrison
CEO, Director
Jul 16, 2026Award+132,000––353,104
Shelia M. Violette
Chief Scientific Officer
Jul 16, 2026Award+37,500––130,569
Isaac Manke
Director
Jun 30, 2026Option exercise+53,521$2.80$149.86K53,521
Capital GP VII LLC OrbiMed
Director, 10% owner
May 28, 2026Buy+1,250,000$8.00$10.00M3,502,987
Capital GP VII LLC OrbiMed
Director, 10% owner
May 28, 2026Buy+625,000$8.00$5.00M625,000
Diyong Xu
Director, 10% owner
May 28, 2026Buy+625,000$8.00$5.00M625,000
Diyong Xu
Director, 10% owner
May 28, 2026Buy+1,250,000$8.00$10.00M3,502,987
Jodie Pope Morrison
CEO, Director
Feb 25, 2026Sale−9,896$4.51$44.63K89,104
Lee Kalowski
CFO and President
Feb 25, 2026Sale−3,995$4.51$18.02K35,943
Shelia M. Violette
Chief Scientific Officer
Feb 25, 2026Sale−2,815$4.51$12.70K55,569
Jodie Pope Morrison
CEO, Director
Feb 24, 2026Award+132,000––221,104
Lee Kalowski
CFO and President
Feb 24, 2026Award+53,250––89,193
Shelia M. Violette
Chief Scientific Officer
Feb 24, 2026Award+37,500––93,069
Jodie Pope Morrison
CEO, Director
Dec 2, 2025Sale−22,506$3.46$77.87K99,000
Lee Kalowski
CFO and President
Dec 2, 2025Sale−9,072$3.46$31.39K39,938
Shelia M. Violette
Chief Scientific Officer
Aug 26, 2025Sale−2,990$1.80$5.38K58,384
Lee Kalowski
CFO and President
Aug 26, 2025Sale−4,240$1.80$7.63K49,010
Jodie Pope Morrison
CEO, Director
Aug 26, 2025Sale−10,494$1.80$18.89K121,506
Lee Kalowski
CFO and President
Feb 24, 2025Award+53,250––53,250
Jason Campagna
Chief Medical Officer
Feb 24, 2025Award+37,500––37,500
Jodie Pope Morrison
CEO, Director
Feb 24, 2025Award+132,000––132,000
Shelia M. Violette
Chief Scientific Officer
Feb 24, 2025Award+37,500––61,374
Shelia M. Violette
Chief Scientific Officer
Oct 15, 2024Option exercise+6,000$7.29$43.74K23,874
Shelia M. Violette
Chief Scientific Officer
Oct 11, 2024Option exercise+4,574$3.12$14.27K17,874
Shelia M. Violette
Chief Scientific Officer
Oct 8, 2024Option exercise+13,300$3.12$41.50K13,300
Arthur Tzianabos
Director
Mar 25, 2024Sale−265$24.20$6.41K7,983
Arthur Tzianabos
Director
Mar 25, 2024Option exercise+1,095––8,248
Paul Alloway
See Remarks
Mar 25, 2024Sale(10b5-1 plan)−268$24.21$6.49K2,596
Charles Michaud Jr
See Remarks
Mar 25, 2024Sale(10b5-1 plan)−75$24.20$1.82K927
Charles Michaud Jr
See Remarks
Mar 25, 2024Option exercise+6,448––18,046
Paul Alloway
See Remarks
Mar 25, 2024Option exercise+23,530––51,566
Arthur Tzianabos
Director
Jan 9, 2024Sale(10b5-1 plan)−13,037$0.57$7.43K128,778
Paul Alloway
See Remarks
Jan 3, 2024Sale(10b5-1 plan)−7,280$0.57$4.15K28,036
Charles Michaud Jr
See Remarks
Jan 3, 2024Sale(10b5-1 plan)−1,708$0.57$97411,598
Arthur Tzianabos
Director
Jan 1, 2024Option exercise+14,280––122,675
Arthur Tzianabos
Director
Jan 1, 2024Option exercise+19,140––141,815
Charles Michaud Jr
See Remarks
Jan 1, 2024Option exercise+1,056––10,666
Charles Michaud Jr
See Remarks
Jan 1, 2024Option exercise+2,640––13,306
Charles Michaud Jr
See Remarks
Jan 1, 2024Option exercise+544––9,610
Paul Alloway
See Remarks
Jan 1, 2024Option exercise+8,910––35,316
Paul Alloway
See Remarks
Jan 1, 2024Option exercise+4,420––21,126
Paul Alloway
See Remarks
Jan 1, 2024Option exercise+5,280––26,406
Albert Seymour
See Remarks, Director
Sep 6, 2023Sale(10b5-1 plan)−1,448$1.15$1.67K150,874
Albert Seymour
See Remarks, Director
Sep 6, 2023Option exercise+4,620––152,322
Julie Jordan
Chief Medical Officer
Aug 3, 2023Sale(10b5-1 plan)−109$1.39$1524,160
Julie Jordan
Chief Medical Officer
Aug 3, 2023Option exercise+387––4,269
Julie Jordan
Chief Medical Officer
Aug 3, 2023Sale(10b5-1 plan)−1,308$1.39$1.82K7,496
Julie Jordan
Chief Medical Officer
Aug 3, 2023Option exercise+1,548––4,318
Julie Jordan
Chief Medical Officer
Aug 3, 2023Sale(10b5-1 plan)−436$1.39$6063,882
Julie Jordan
Chief Medical Officer
Aug 3, 2023Option exercise+4,644––8,804
Julie Jordan
Chief Medical Officer
Aug 2, 2023Option exercise+350––2,869
Julie Jordan
Chief Medical Officer
Aug 2, 2023Sale(10b5-1 plan)−99$1.31$1302,770
Paul Alloway
See Remarks
Mar 2, 2023Sale(10b5-1 plan)−10,965$1.45$15.90K16,706

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
26.43%
6M shares short
Days to cover
12.1
At 0M shares a day
Change since last report
-1.1%
From 6M shares
Short volume, 20 days
51.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Q32 Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 46,559 shares on Sep 30, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Lee Kalowski
Officer
Dec 2, 20259,072$31.40KDec 2, 2025Restricted Stock
Jodie Pope Morrison
Officer, Director
Dec 2, 202522,506$77.87KDec 2, 2025Restricted Stock

See a number that looks wrong?